The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
Abstract
PURPOSE: The specific aims of this study were to improve event-free survival (EFS) in patients with newly diagnosed nonmetastatic osteosarcoma of an extremity using the histologic response to neoadjuvant chemotherapy to determine postoperative chemotherapy; to evaluate a uniform histologic grading system that measures tumor response; and to identify patient characteristics that might influence EFS and survival. PATIENTS AND METHODS: Two hundred sixty-eight patients with nonmetastatic osteosarcoma of the extremity were entered between August 1983 and October 1986. Preoperative chemotherapy consisted of four courses of high-dose methotrexate (MTX) and one course of bleomycin, cyclophosphamide, and dactinomycin (BCD). Histologic response to preoperative chemotherapy was determined by morphometric analysis. Good histologic responders (< 5% residual viable tumor) were treated postoperatively with MTX, BCD, and doxorubicin (DOX); poor histologic responders were treated with BCD, DOX, and cisplatin (CDDP). RESULTS: The 8-year EFS and survival rates were 53% and 60%, respectively. Two hundred six patients had their tumors assessed for histologic response: 28% displayed a good histologic response to preoperative chemotherapy. Good histologic responders had an 8-year postoperative EFS rate of 81% and survival rate of 87%; those with a poor histologic response had an 8-year postoperative EFS rate of 46% and survival rate of 52%. A primary tumor site in the proximal humerus or proximal femur and an elevated serum alkaline phosphatase level were associated with an increased risk of an adverse event, whereas the type of surgical procedure was not. CONCLUSION: EFS and survival appear to be directly related to histologic response to neoadjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Self-citationChemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Self-citationPrimary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Self-citationAdjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 529
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
MARCOVE, R. C., MIKÉ, V., HAJEK, J. V., LEVIN, A. G., & HUTTER, R. V. P. (1970) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197052030-00001 · Cited by 361
Cited by
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citationBiology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006) · Cancer · doi:10.1002/cncr.21724 · Cited by 569
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Self-citationOsteosarcoma (Osteogenic sarcoma)
Picci, P. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-6 · Cited by 505
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4016 · Cited by 438
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Goorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 395
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Picci, P., Tienghi, A., Del Prever, A. B., Fagioli, F., Comandone, A., & Bacci, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.141 · Cited by 316
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Self-citationMeyers, P. A., & Gorlick, R. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70540-x · Cited by 299
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Current Treatment of Osteosarcoma
Ferguson, W. S., & Goorin, A. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100102557 · Cited by 295
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Self-citationOsaki, M., Takeshita, F., Sugimoto, Y., Kosaka, N., Yamamoto, Y., Yoshioka, Y., Kobayashi, E., Yamada, T., Kawai, A., Inoue, T., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.53 · Cited by 271
Messerschmitt, P. J., Garcia, R. M., Abdul-Karim, F. W., Greenfield, E. M., & Getty, P. J. (2009) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200908000-00005 · Cited by 260
Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology
Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248
Hawkins, D. S., Rajendran, J. G., Conrad, E. U., Bruckner, J. D., & Eary, J. F. (2002) · Cancer · doi:10.1002/cncr.10599 · Cited by 257
Bacci, G., Bertoni, F., Longhi, A., Ferrari, S., Forni, C., Biagini, R., Bacchini, P., Donati, D., Manfrini, M., Bernini, G., et al. (2003) · Cancer · doi:10.1002/cncr.11456 · Cited by 253
Osteosarcoma: Review of the Past, Impact on the Future. The American Experience
Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_12 · Cited by 252
Ferrari, S., Bacci, G., Picci, P., Mercuri, M., Briccoli, A., Pinto, D., Gasbarrini, A., Tienghi, A., & Brach del Prever, A. (1997) · Annals of Oncology · doi:10.1023/a:1008221713505 · Cited by 116
“In the CCG-782 study [12], patients were preoperatively treated with HDMTX, vincristine (VCR) and BCD; the postoperative treatment consisted of a common phase based on MTX, BCD and ADM, and a subsequent phase differentiated according to histologic response: patients with more than 95% tumor necrosis (good histologic r…”
MethodResultBishop, M. W., Chang, Y., Krailo, M. D., Meyers, P. A., Provisor, A. J., Schwartz, C. L., Marina, N. M., Teot, L. A., Gebhardt, M. C., Gorlick, R., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26034 · Cited by 52
“The long-term survival rate for localized osteosarcoma has remained around 65–70% for decades;[1,2,20–22] to date, histologic necrosis remains the only consistently significant prognostic factor for survival for patients with localized disease.[3,6,10, 12,20,23] However, our results demonstrate an inverse relationship…”
BackgroundMethodInfluentialSelf-citationTreatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide
Rodríguez-Galindo, C., Daw, N. C., Kaste, S. C., Meyer, W. H., Dome, J. S., Pappo, A. S., Rao, B. N., & Pratt, C. B. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200205000-00006 · Cited by 40
Metadata
- Authors
- Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., & Miser, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-01
- Volume
- 15
- Issue
- 1
- Pages
- 76-84
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1854116296
- Cited by
- 461
- References
- 15
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.